Mitchell Lawrence Jones - 06 Jul 2026 Form 4 Insider Report for PALISADE BIO, INC. (PALI)

Reporting relationship: Chief Medical Officer
Issuer ticker: PALI
Reported as of: 06 Jul 2026
Net transaction value: -$106,536
SEC form: 4
Accepted by SEC: 08 Jul 2026, 18:52:59 UTC
Prior SEC filing: 13 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Ryker Willie, Attorney-in-Fact for Mitchell Lawrence Jones

Key filing fact

Mitchell Lawrence Jones filed Form 4 for PALISADE BIO, INC. (PALI) on 08 Jul 2026.

Key facts

This page summarizes Mitchell Lawrence Jones's Form 4 filing for PALISADE BIO, INC. (PALI).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Jul 2026, 18:52.

Change

Previous filing in this sequence was filed on 13 Feb 2026.
Current net transaction value: -$106,536.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001993292 Primary reporting owner

Jones Mitchell Lawrence

Relationship: Chief Medical Officer
Address: C/O PALISADE BIO, INC., 4600 SOUTH SYRACUSE STREET, SUITE 900, DENVER
Signature: /s/ Ryker Willie, Attorney-in-Fact for Mitchell Lawrence Jones
Signature date: 08 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PALI transaction

Common Stock

Options Exercise

Transaction value
Shares: +131,167
Change %: +891%
Price
Shares after: 145,889
Date: 06 Jul 2026
Ownership: Direct
Footnotes: F1, F2

PALI transaction

Common Stock

Sale

Transaction value: $106,536
Shares: -51,880
Change %: -36%
Price: $2.05
Shares after: 94,009
Date: 07 Jul 2026
Ownership: Direct
Footnotes: F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PALI transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -131,167
Change %: -17%
Price: $0.000000^*
Shares after: 655,833
Date: 06 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 131,167
Exercise price
Footnotes: F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") granted on February 9, 2026.

Footnote F2

Includes 1,459 shares acquired under the Issuer's Employee Stock Purchase Plan on May 20, 2026.

Footnote F3

The sale reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.045 to $2.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F5

Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Footnote F6

The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following 10 quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.